#United States #Cambridge #Sleep Apnea #Apnimed #AD109

Apnimed’s Participation in July Conferences

Apnimed, Inc. is thrilled to announce its participation in notable investor conferences during July 2025. As a clinical-stage pharmaceutical firm based in Cambridge, Massachusetts, Apnimed is on a mission to revolutionize treatment methods for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The company is committed to developing first-in-class oral drug candidates designed to tackle fundamental problems associated with these conditions.

Conference Details

Apnimed will be actively involved in the following key conferences in July:

• - Evercore's Emerging Private Biotech Conference

Dates: July 13 - 15, 2025
Apnimed will join other innovators in discussing advancements and innovations in the biotech sector.

• - BTIG Virtual Biotechnology Conference 2025

Dates: July 29 - 30, 2025
As part of this conference, Apnimed will organize one-on-one meetings with interested investors on the second day, July 29, 2025. Investors wishing to meet with Apnimed can get in touch with their BTIG representatives directly to schedule these meetings.

Apnimed's Mission

Apnimed aims to redefine the treatment landscape for sleep-related breathing disorders by highlighting the need for accessible and effective therapies for conditions like OSA. Recognizing that OSA shares similarities with other chronic diseases, including diabetes and hypertension, the company believes in the importance of offering a variety of treatment options that can address the diverse nature of these conditions.

With a focus on developing simple, once-nightly oral drugs, Apnimed positions itself to enhance the diagnosis and treatment approaches for individuals suffering from OSA. This shift is essential, as it could broaden access to critical treatments and ultimately improve the quality of life for patients.

Lead Product Candidate: AD109

Leading the charge in Apnimed's portfolio is their investigational drug candidate, AD109. This promising product is currently undergoing Phase 3 clinical trials targeting mild, moderate, and severe cases of OSA. AD109 is touted as a potential game-changer in the treatment of OSA by providing a straightforward and non-invasive alternative to existing cumbersome devices and surgeries.

Joining Forces with Shionogi

Additionally, Apnimed is developing several therapies through a collaboration with Shionogi & Co., Ltd., known as the Shionogi-Apnimed Sleep Science venture. This partnership emphasizes Apnimed’s commitment to expanding its treatment offerings and advancing medical research in sleep medicine.

Looking Ahead

As Apnimed prepares for these conferences, the company remains dedicated to advancing its innovative therapies and addressing the unmet medical needs of patients with sleep-related breathing disorders. Attendees of the conferences will have a unique opportunity to learn more about Apnimed’s promising treatment options and the company’s vision for the future of sleep medicine.

For more information about Apnimed and its endeavors, visit apnimed.com or follow the company’s updates on social media platforms such as X and LinkedIn.

Media and Investor Contacts

For media inquiries, please reach out to [email protected]. Investors can direct their questions to Ramzi Benamar at [email protected]

With its innovative approach and upcoming engagements, Apnimed is set to make a significant impact on the future of treatments for obstructive sleep apnea and related conditions, marking a new era in patient care.